Saturday 17 October 2026
Export HRMY’s income statement to Excel — free account
Harmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024. In the quarter to June 2026, revenue grew 30.3%, EPS grew 88.4%, free cash flow grew 16.5% and total debt fell 10.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.
38.20
0.07
−0.18%
Follow HRMY
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
7 | 5 | 4 | 4 |
| 25.93% | 20.75% | 17.86% | 20.46% | ||
| 17.38% | 13.98% | 12.51% | 14.61% | ||
ROIC |
42.60% | 50.40% | 27.66% | 29.70% | |
Return on Tangible Assets |
30.10% | 24.23% | 25.93% | 31.24% | |
Average Days of Receivables |
44.48 | 40.68 | 43.93 | 42.21 | |
Free Cash Flow per Share |
5.16 | 6.05 | 5.91 | 6.13 | |
Free Cash Flow |
296.89 | 347.89 | 341.97 | 355.08 | |
Capital Expenditures |
(0.72) | (0.31) | — | — | |
| Other line items | |||||
Cash ROIC |
17.71% | 19.23% | 20.00% | 19.50% | |
Accounts Receivable Turnover |
9.07 | 9.66 | 8.40 | 9.41 | |
Accounts Payable Turnover |
9.99 | 12.62 | 9.16 | 9.44 | |
Inventory Turnover |
26.70 | 31.60 | 36.15 | 37.87 | |
Average Days of Payables |
52.19 | 32.56 | 49.51 | 33.55 | |
Days of Inventory on Hand |
13.64 | 9.86 | 9.14 | 9.84 | |
Tax Rate |
(0.19) | (0.26) | (0.26) | (0.25) | |
Research and Development Expense of Revenue |
21.11% | 21.83% | 24.96% | 23.01% | |
Selling, General and Administrative Expense of Revenue |
29.27% | 31.33% | 30.51% | 28.39% | |
Share Based Compensation of Revenue |
5.45% | 5.17% | 4.78% | 4.26% | |
Interest Coverage |
14.74 | 14.23 | 13.49 | 17.12 | |
Operating CF/Net income |
1.60 | 2.19 | 2.35 | 1.96 | |
Depreciation/Fixed assets |
15.83 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.03) | (0.01) | 0.00 | 0.00 | |
Revenue per Share |
14.35 | 15.11 | 15.55 | 16.57 | |
Operating CF per Share |
5.17 | 6.06 | 5.91 | 6.13 | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates